国际干细胞公司 (ISCO) 是一家上市的临床阶段生物技术公司，拥有强大的新干细胞技术，称为人类孤雌生殖激活，有望显着推动再生医学领域的发展。
孤雌生殖（来自希腊语parthenos 意为“处女”和 genesis 意为“出生”）激活利用未受精的人类卵子来创造可以与数百万人免疫匹配的孤雌生殖干细胞 (hpSC)。因此，相对少量的 hpSC 系可以提供足够的免疫匹配细胞来覆盖世界人口的很大一部分。
ISCO 的科学家专注于使用 hpSC 治疗神经系统、关节和肝脏的严重疾病，这些疾病的细胞疗法已被证明在临床上有效，但受到安全免疫匹配人类细胞可用性的限制。
International Stem Cell Corporation (ISCO) is a publicly traded clinical stage biotechnology company with a powerful new stem cell technology called human parthenogenetic activation that promises to significantly advance the field of regenerative medicine.
Parthenogenetic (from the Greek parthenos meaning “virgin” and genesis meaning “birth”) activation utilizes unfertilized human eggs to create parthenogenetic stem cells (hpSC) that can be immune-matched to millions of people. As a result, a relatively small number of hpSC lines could provide enough immune-matched cells to cover a large percentage of the world’s population.
ISCO’s scientists are focused on using hpSC to treat severe diseases of the nervous system, joints and liver where cell therapy has been proven clinically effective but is limited by the availability of safe immune-matched human cells.